2022 American Transplant Congress
Impact of Belatacept on Clinical Outcomes in Lung Transplant Patients with Antibody-Mediated Rejection
*Purpose: Antibody-mediated rejection (AMR) is cause of significant morbidity and mortality in lung transplant recipients (LTRs). An optimal therapeutic regimen is still lacking. Recent evidence…2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…2022 American Transplant Congress
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
*Purpose: Post-transplant immunosuppression with “everolimus + reduced dose tacrolimus” (Ev + Taclow) is reported to reduce the risk of viral infections compared to standard doses…2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…2022 American Transplant Congress
Pegloticase Use in Renal Transplant Recipients with Gout: Findings from an Insurance Claims Database Study
1Iowa Kidney Physicians, Des Moines, IA, 2Horizon Therapeutics plc, Deerfield, IL
*Purpose: Kidney transplant (KT) recipients have high gout incidence due to reduced eGFR and medication use associated with hyperuricemia.1 Oral urate-lowering therapies in KT patients…2022 American Transplant Congress
Comparing The Immunologic Responses Between Kidney Transplant Recipients Receiving Standard Immunosuppression And CNI Reduction After Two Doses Of ChAdOx-1 And A Booster Dose BNT162b2
*Purpose: Immunosuppression can impair immunological responses after vaccination in kidney transplant recipients (KTR). However, little is known about the effect of the booster dose of…2022 American Transplant Congress
Recipient and Center Factors Associated with Immunosuppression Practice Beyond the First Year After Liver Transplantation
1University of Pennsylvania, Philadelphia, PA, 2University of Miami, Miami, FL
*Purpose: To investigate patient and center factors associated with differences in immunosuppression management in the first 5 years after LT.*Methods: A retrospective cohort of 11,326…2022 American Transplant Congress
A Low Immuknow Level but Behold….pAMR1(H+) Rejection
Tampa General Hospital, Tampa, FL
*Purpose: PURPOSE: The purpose of this study is to evaluate the mechanism of pAMR1(H+) rejection in heart transplant recipients with low ImmuKnow levels (ATP2022 American Transplant Congress
Association Between Maintenance Immunosuppressive Regimens And Covid-19 Mortality In Kidney Transplant Recipients
*Purpose: Kidney transplant recipients (KTR) are at increased risk of mortality from COVID-19. We conducted a cohort study among KTR from the French Solid Organ…2022 American Transplant Congress
Recurrence of Focal Segmental Glomerulosclerosis After Kidney Transplantation According to Pre-Transplant Treatment
Department of general surgery, Asan Medical Center, Seoul, Korea, Republic of
*Purpose: Focal segmental glomerulosclerosis (FSGS) recurrence after kidney transplantation (KT) is a significant risk factor of graft failure. The recurrence of FSGS develops in 30%-60%…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 138
- Next Page »